P&U Colestid OTC development investment of over $6 mil. includes consumer use study.
This article was originally published in The Tan Sheet
Executive Summary
COLESTID OTC DEVELOPMENT INVESTMENT OF OVER $6 MIL. since 1989 includes expenditures on a consumer use study in several major urban markets, according to Pharmacia & Upjohn. The company initiated the study in January and expects to complete the project at the end of 1997. Information regarding the company's program to switch its prescription cholesterol-reducing drug Colestid (colestipol) to OTC status was disclosed by Pharmacia & Upjohn in a trademark infringement lawsuit filed against Pharmanex last spring in Grand Rapids, Mich. federal court.